Lupus Nephritis

NEW YORK, N.Y. — September 23, 2026 Lupus Research Alliance (LRA) announced the recipients of its 2026 Translational Bridge...

SAN DIEGO — September 9, 2026 Fate Therapeutics, Inc. announced that new clinical data for its off-the-shelf anti-CD19 CAR...

SOUTH SAN FRANCISCO, California — September 8, 2026 Nkarta, Inc. announced that three scientific presentations featuring NKX019 have been...

REDWOOD CITY, Calif., September 1, 2026 Adicet Bio announced completion of the last patient visit for the planned Phase...

San Diego, California — August 14, 2026 Fate Therapeutics, Inc. has initiated the potentially registrational RECLAIM-LN Phase 2 clinical...

RESEARCH TRIANGLE PARK, N.C., July 15, 2026 Persephoni BioSciences has announced a strategic investment in SelSym Biotech, bringing the...

SOUTH SAN FRANCISCO, Calif., July 14, 2026 Genentech, a member of the Roche Group, has received U.S. Food and...

SAN DIEGO, July 6, 2026 Fate Therapeutics announced that preliminary clinical data from its investigational FT819 off-the-shelf CD19-targeting CAR...

ROCKVILLE, Maryland and EDMONTON, Alberta, July 6, 2026 Aurinia Pharmaceuticals Inc. announced the initiation of PRESERVE, a Phase 4,...

MISSISSAUGA, Ontario, May 22, 2026 Roche Canada announced that Canada’s Drug Agency (CDA-AMC) has issued a positive reimbursement recommendation...